Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 2interventionalRules rewrite

Phase 2: testing icovamenib 100 mg for Type 2 Diabetes

This is a phase 2 randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment trial assessing the how well it works and safety of icovamenib in participants with Type 2 Diabetes (T2D) not achieving glycemic targets despite GLP-1-based therapy.

Official registry: https://clinicaltrials.gov/study/NCT07502508 · Biomea Fusion Inc. · enrollment listed as 60

What this phase means

Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are icovamenib 100 mg, or Placebo. The registry lists allocation as randomized. This is a phase 2 randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment trial assessing the how well it works and safety of icovamenib in participants with Type 2 Diabetes (T2D) not achieving glycemic targets despite GLP-1-based therapy.

They plan to enroll about 60 people at 20 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

Phase 2 Randomized, Double-blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Icovamenib in Participants With Type 2 Diabetes Not Achieving Glycemic Targets Despite GLP-1-Based Therapy

Interventions: icovamenib 100 mg, Placebo

Primary outcome (registry wording): To demonstrate that icovamenib 100 mg once daily for 12 weeks is superior to placebo for glycemic control

Who it is for (from inclusion criteria)

  • Ages 18 Years to 75 Years
  • Males or females, age ≥18 years and ≤75 years
  • Have been diagnosed with T2D
  • Have HbA1c ≥7.0 and ≤10.5%
  • Have a body-mass index (BMI) 25 to 45 kg/m2
  • Female participants of childbearing potential must have a negative pregnancy test, must be non-lactating, must be willing to have additional pregnancy tests during the study, must agree to the sex and contraception requirements

Public study contact (from the registry)

Biomea Fusion Inc.

8442450490

clinicaltrials@biomeafusion.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

20 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseSan Antonio, Texas
Not a traditional drug phase: testing Dapagliflozin for Diabetes Mellitus, Type 2

HYPOTHESIS: Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have distinct pathophysiologic etiologies. Therefore, therapeutic interventions designed to correct the specific underlying pathogenic abnormalities in IGT and IFG will be required to optimally prevent the progressive beta cell failure and development of overt type 2 diabetes.

NCT02969798 · Official ClinicalTrials.gov record · The University of Texas Health Science Center at San Antonio

RecruitingNot a traditional drug phaseMontreal, Quebec
Not a traditional drug phase: Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE) for Nonalcoholic Fatty Liver Disease (NAFLD)

Nonalcoholic fatty liver disease is the most common liver disease in Western countries, due in large part to its association with type 2 diabetes and obesity. The more advanced form of this disease is known as nonalcoholic steatohepatitis (NASH).

NCT03572465 · Official ClinicalTrials.gov record · Centre hospitalier de l'Université de Montréal (CHUM)

FAQ about this NCT record

Is NCT07502508 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07502508?

Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07502508?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary